GSK plc (GSK.L) Monday said its investigational drug in chronic hepatitis B bepirovirsen received Fast Track designation from the US Food and Drug Administration (FDA).
The designation was supported by data from the phase IIb trials B-Clear and B-Sure, which evaluated the efficacy, safety and durability of response of bepirovirsen in people with chronic hepatitis B.
A confirmatory Phase 3 study of bepirovirsen dubbed B-Well, is ongoing.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.